GSK is on the brink of EU approval for JAK inhibitor momelotinib as a treatment for myelofibrosis patients with anaemia, after the EMA’s human medicines committee issued a
GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquire
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh